翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年12月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年12月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變 ...

证券日报网讯 12月16日，昊海生科在互动平台回答投资者提问时表示，公司始终坚持聚焦主业，通过 扎实做好生产经营、持续提升核心竞争力和内在价值，并关注行业内发展机会，力争实现稳健发展，以 切实的经营业绩回报广大投资者的信任。具体资金使用情况及用途，敬请关注公司公告。 （文章来源：证券日报） ...

Group 1 - The core point of the article highlights that as of December 15, a total of 165 stocks in the Shanghai and Shenzhen markets have experienced net buying from main funds for five consecutive days or more [1] - The stock with the longest consecutive net buying days is Haohai Biological Technology, which has seen net buying for 15 consecutive trading days [1] - Other stocks with significant consecutive net buying days include Longteng Optoelectronics, China National Materials, Jianyan Institute, Xinhua Medical, Phoenix Shares, Huawang Technology, Hongdou Shares, and Baihe Shares [1]

Core Viewpoint - As of December 12, a total of 201 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Significant Net Buying - The stock with the longest consecutive net buying days is Haohai Biological Technology, which has seen net buying for 14 consecutive trading days [1] - Other notable stocks with significant net buying days include Longteng Optoelectronics, Jianyan Institute, Oppein Home, China Shenhua, China National Materials, Zhongchi Holdings, Xinhua Medical, and Phoenix Holdings [1]

Core Viewpoint - Haohai Biology is expanding its business by acquiring a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for 38.35 million yuan, aiming to enter the high-value medical device sector of biological amniotic membrane, despite Ruiji's ongoing financial losses and lack of performance guarantees in the transaction [1][3]. Group 1: Acquisition Details - The acquisition involves Haohai Biology purchasing 8.4661 million shares of Ruiji, which has been struggling with losses of 11.77 million yuan last year and 11.29 million yuan in the first three quarters of this year [1][2]. - The transaction does not grant Haohai Biology control over Ruiji's existing team or decision-making on financial and operational matters, as the stake does not allow for consolidation in Haohai's financial reports [2]. Group 2: Financial Performance of Haohai Biology - Haohai Biology's core business has been under pressure, with a revenue decline of 7.12% and a net profit drop of 10.29% in the first half of this year compared to the previous year [1][5]. - The company reported a revenue of 2.698 billion yuan and a net profit of 420 million yuan last year, with growth rates slowing significantly [5]. - In the first three quarters of this year, Haohai's revenue was 1.899 billion yuan, down 8.47%, and net profit was 305 million yuan, down 10.63% [7]. Group 3: Market Context and Competition - The global amniotic membrane market is projected to grow from over 1.89 billion dollars last year to 3.97 billion dollars by 2034, with a compound annual growth rate of approximately 7.7% [8]. - Competition in the biological amniotic membrane sector is intensifying, with other companies like Guangzhou Ruitai Biological and Chengdu Qingshan Likang Pharmaceutical also entering the market [9]. - Analysts suggest that while the acquisition may provide strategic benefits, the ongoing losses and competitive landscape present significant challenges for Haohai Biology [9].

Core Viewpoint - Haohai Biological Technology (昊海生科) plans to invest in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. (瑞济生物) to enter the high-value biological amniotic membrane market despite experiencing a decline in revenue and net profit [1][4]. Group 1: Investment Details - Haohai will acquire a total of 19.8% of Ruiji Biological's shares through a framework agreement, paying 38.35 million yuan and 4.76 million yuan in three phases for 8.4661 million shares and 1.0499 million shares respectively [1][3]. - The transaction price is set at 4.53 yuan per share, based on the market price before Ruiji Biological's delisting from the National Equities Exchange and Quotations [3][9]. Group 2: Company Background - Ruiji Biological, established in 2002, specializes in the production and sale of biological amniotic membranes, which are classified as Class III medical devices used in orthopedic and ophthalmic fields [1][3]. - Haohai aims to enhance its product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors by obtaining distribution rights for Ruiji's products in China [3][9]. Group 3: Financial Performance - Ruiji Biological reported revenues of approximately 46.36 million yuan and 46.09 million yuan for 2024 and the first three quarters of 2025, respectively, with net losses of 11.77 million yuan and 11.29 million yuan [4][10]. - Haohai's revenue for the first three quarters of this year was about 1.899 billion yuan, a year-on-year decrease of 8.47%, with a corresponding net profit of approximately 305 million yuan, down 10.63% year-on-year [4][10]. Group 4: Risks and Challenges - The transaction does not include performance commitments or earn-out arrangements, which means there are risks associated with potential underperformance of Ruiji Biological [4][10]. - Market conditions and sales channels may affect the sales performance of the acquired products, posing risks of reduced investment returns and failure to achieve acquisition objectives [5][10].

Core Viewpoint - Haohai Biological Technology (688366) plans to enter the high-value biological amniotic membrane market despite a decline in revenue and net profit, through acquiring a 19.8% stake in Ruijibio [1][3][5]. Group 1: Company Acquisition Details - Haohai Biological signed a share transfer framework agreement to acquire shares from Ruijibio's existing shareholders for a total of approximately 43.91 million yuan [1]. - The acquisition price is set at 4.53 yuan per share, based on the market price before Ruijibio's delisting from the National Equities Exchange and Quotations [3]. - Ruijibio specializes in producing and selling biological amniotic membranes, which are classified as Class III medical devices used in orthopedic and ophthalmic fields [1][3]. Group 2: Financial Performance - Ruijibio reported revenues of approximately 46.36 million yuan and 46.09 million yuan for 2024 and the first three quarters of 2025, respectively, with net losses of 11.77 million yuan and 11.29 million yuan [4]. - Haohai Biological's revenue for the first three quarters of this year was approximately 1.899 billion yuan, a year-on-year decrease of 8.47%, while net profit was about 305 million yuan, down 10.63% year-on-year [5]. Group 3: Strategic Implications - The investment in Ruijibio is expected to enhance Haohai Biological's product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors [3]. - The biological amniotic membrane materials possess human-derived biological characteristics, providing a significant technological and material foundation for research and development in regenerative medicine and tissue engineering [3].

Core Viewpoint - Haohai Biology has acquired a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for 38.35 million yuan, aiming to enter the high-value medical device sector of biological amniotic membranes, despite Ruiji's ongoing financial struggles and lack of performance guarantees in the transaction [1][4]. Group 1: Acquisition Details - The acquisition involves Haohai Biology purchasing 8.4661 million shares of Ruiji, which has been facing financial difficulties with losses of 11.77 million yuan in 2024 and 11.29 million yuan in the first nine months of 2025 [1][3]. - The transaction does not include any performance commitments or earn-out arrangements, posing a risk of investment loss if Ruiji's performance declines further [4]. Group 2: Haohai Biology's Business Context - Haohai Biology, the first biopharmaceutical company listed on both the Hong Kong Stock Exchange and the Sci-Tech Innovation Board, has seen a decline in its core business, with revenue and net profit dropping by 7.12% and 10.29% respectively in the first half of 2025 [1][6]. - The company reported a revenue of 2.698 billion yuan and a net profit of 420 million yuan in 2024, but growth has stagnated, with significant declines in its medical aesthetics, ophthalmology, and orthopedics segments [6][7]. Group 3: Market Potential and Competition - The global amniotic membrane market is projected to grow from 1.89 billion USD in 2024 to 3.97 billion USD by 2034, with a compound annual growth rate of approximately 7.7% [8]. - Competition in the biological amniotic membrane sector is intensifying, with other companies like Guangzhou Ruitai Biological and Chengdu Qingshan Likang Pharmaceutical also entering the market [9].

Core Viewpoint - Huaxi Biological, a leading player in the medical beauty industry, is currently facing significant challenges as the hyaluronic acid market experiences diminishing returns, leading to a decline in revenue and profit [3][5]. Group 1: Financial Performance - In the first three quarters of this year, Huaxi Biological's revenue decreased by 18.36% to 3.163 billion yuan, while net profit attributable to shareholders fell by 30.29% to 252 million yuan [5]. - As of December 5, Huaxi Biological's stock closed at 45.57 yuan, below its IPO price of 47.79 yuan, with a market capitalization of only 22 billion yuan, a drop from its peak of 140 billion yuan [5]. - By the third quarter of 2025, the company's revenue was 903 million yuan, down 15.16%, while net profit attributable to shareholders increased by 55.63% to 32 million yuan [14]. Group 2: Product and Brand Strategy - Huaxi Biological's skincare products, primarily based on hyaluronic acid, have seen a significant revenue decline, with a 33.97% drop in the first half of 2025, contributing to 40.36% of the company's main business revenue [9]. - The company has decided to eliminate several underperforming sub-brands, including Runxihe, Runxiquan, and Demarun, in an effort to focus on its core brands [9][11]. - The revenue from core brands like Kuadi and Runbaiyan has also shown signs of fatigue, with both brands expected to fall below the 1 billion yuan revenue mark by 2024 [10][17]. Group 3: Market Dynamics - The cosmetic market is experiencing intense competition, with a significant increase in the number of hyaluronic acid products, leading to market saturation and reduced consumer interest [16]. - The price war in the hyaluronic acid sector has intensified, with products like Joia's hyaluronic acid being sold at drastically reduced prices, marking the end of high-profit margins in the industry [17]. - The overall market for functional skincare products is projected to reach 211.8 billion yuan by 2025, with collagen expected to surpass hyaluronic acid as the leading ingredient [21]. Group 4: Future Outlook - Huaxi Biological is undergoing a transformation, shifting its focus from skincare to new areas such as weight loss and small nucleic acid drugs, investing 138 million yuan in a strategic partnership with Saint Pharma [24]. - The company is rebranding its skincare product line to emphasize technological innovation, indicating a shift in strategy to adapt to changing market conditions [24].